Nouvelles fluoroquinolones et pneumonies aiguës communautaires (PAC)

a mise à disposition en France des nouvelles fluoroquinolones, ou encore fluoroquinolones antipneumococciques, s’inscrit dans un contexte particulier : ! prise de conscience de la consommation excessive d’antibiotiques ; ! crainte de voir se renouveler pour la famille des quinolones antipneumococciques l’expérience de la résistance de Streptococcus pneumoniae vécue avec les bêtalactamines et les macrolides ; ! recherche d’une sécurité d’utilisation maximale pour une famille dont plusieurs spécialités ont vu leur développement arrêté, ou leur retrait du marché ; ! évolution des résistances de S. pneumoniae.

[1]  E. Varon,et al.  Résistance aux antibiotiques : le modèle bêta-lactamines est-il transposable aux fluoroquinolones ? , 2002 .

[2]  H. Chardon,et al.  Épidémiologie de la résistance du pneumocoque aux antibiotiques , 2002 .

[3]  J. Hutchinson Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. , 2002, The New England journal of medicine.

[4]  L. Mandell,et al.  Interspecies Recombination Contributes Minimally to Fluoroquinolone Resistance in Streptococcus pneumoniae , 2001, Antimicrobial Agents and Chemotherapy.

[5]  D. Low,et al.  A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Otite Moyenne Aiguë ANTIBIOTHERAPIE PAR VOIE GENERALE EN PRATIQUE COURANTE , 2001 .

[7]  Y. Mouton,et al.  Révision de la IVe Conférence de consensus en thérapeutique anti-infectieuse de la Société de pathologie infectieuse de langue française (SPILF) , 2001 .

[8]  M. Fine,et al.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. , 2001, American journal of respiratory and critical care medicine.

[9]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  L. Mandell,et al.  Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Liñares,et al.  Horizontal Transfer of parC and gyrA in Fluoroquinolone-Resistant Clinical Isolates ofStreptococcus pneumoniae , 2000, Antimicrobial Agents and Chemotherapy.

[12]  L. Mandell,et al.  Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. , 2000, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[13]  J. Liñares,et al.  Fluoroquinolone resistance in Streptococcus pneumoniae. , 1999, The New England journal of medicine.

[14]  L. Piroth,et al.  Development of a New Experimental Model of Penicillin-ResistantStreptococcus pneumoniae Pneumonia and Amoxicillin Treatment by Reproducing Human Pharmacokinetics , 1999, Antimicrobial Agents and Chemotherapy.

[15]  L. Gutmann,et al.  In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. , 1999, The Journal of infectious diseases.

[16]  D E Low,et al.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.

[17]  J. Justman,et al.  Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  T. Ng,et al.  Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong , 1999, Antimicrobial Agents and Chemotherapy.

[19]  M. R. Jacobs,et al.  In Vitro Development of Resistance to Five Quinolones and Amoxicillin-Clavulanate in Streptococcus pneumoniae , 1999, Antimicrobial Agents and Chemotherapy.

[20]  L. Gutmann,et al.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA , 1996, Antimicrobial agents and chemotherapy.